Calamos Advisors’s European Biotech Acquisition Corp. Warrant EBACW Stock Holding History

Calamos Advisors’s Portfolio EBACW Stock Details EBACW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-33,333	Closed	-$8.33K	–	1293
2022 Q4	$8.33K	Hold	33,333	–	–	﹤0.01%	1117
2022 Q3	$2K	Buy	+33,333	New	+$3.64K	﹤0.01%	1247

Calamos Advisors's EBACW Position: Q1 2023 in Review

Calamos Advisors sold out of European Biotech Acquisition Corp. Warrant (EBACW) in Q1 2023, closing a stake of 33,333 shares — an estimated $8.33K sold.

Calamos Advisors first reported a position in EBACW in Q3 2022 and held it in 2 quarters. The position peaked at $8.33K in Q4 2022. 0 funds tracked by Wall St. Rank hold EBACW as of Q1 2023.

Calamos Advisors reported no remaining European Biotech Acquisition Corp. Warrant position as of Q1 2023 after selling out during the quarter.
Calamos Advisors sold 33,333 European Biotech Acquisition Corp. Warrant shares in Q1 2023, an estimated $8.33K.
Calamos Advisors first reported a position in European Biotech Acquisition Corp. Warrant in Q3 2022 and held it in 2 quarters.
Calamos Advisors's European Biotech Acquisition Corp. Warrant position peaked at $8.33K in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Warrant as of Q1 2023.

Based on Calamos Advisors's 13F filing for Q1 2023, filed 4 May 2023.